Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer | Zendy

Elisa Van Raemdonck | Zendy; Giuseppe Floris | Zendy; Patrick Berteloot | Zendy; Annouschka Laenen | Zendy; Ignace Vergote | Zendy; Hans Wildiers | Zendy; Kevin Punie | Zendy; Patrick Neven | Zendy

Open Access

Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer

Author(s) -

Elisa Van Raemdonck,

Giuseppe Floris,

Patrick Berteloot,

Annouschka Laenen,

Ignace Vergote,

Hans Wildiers,

Kevin Punie,

Patrick Neven

Publication year - 2020

Publication title -

breast cancer research and treatment

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.908

H-Index - 154

eISSN - 1573-7217

pISSN - 0167-6806

DOI - 10.1007/s10549-020-05935-5

Subject(s) - trastuzumab , lapatinib , pertuzumab , medicine , metastatic breast cancer , oncology , trastuzumab emtansine , taxane , breast cancer , capecitabine , proportional hazards model , cancer , colorectal cancer

In stage IV breast cancer, the efficacy of human epidermal growth factor receptor 2 (HER2) targeted therapies in cases with discordance in HER2 expression between primary and metastatic site is not well known. We studied progression free (PFS) and overall survival (OS) by HER2 concordance when treating women with taxane-trastuzumab (± pertuzumab) in first or second line and trastuzumab-emtansine (T-DM1) or capecitabine-lapatinib in later lines.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research